How effective is genomic tumour profiling for lung cancer?

A sample from the tumour, or sometimes a blood sample containing tumour material, is examined for genetic changes. The report may show a change linked with a targeted medicine, an immune-treatment decision, a clinical trial option, or no currently useful match. A finding can guide the next discussion without proving that a treatment will work. Results also depend on whether the sample contains enough tumour cells and whether the tested tissue reflects the cancer that is active now.

Ask the oncology team which test is being used, whether tissue or blood is more suitable, and when the report is expected. Review the result alongside the cancer type, stage, previous treatment, other health conditions, and your preferences. If a potentially actionable change is found, ask what treatment it opens up and how response will be monitored. If no match is found, standard treatments may still be appropriate.

Contact your cancer team promptly for new or worsening breathlessness, chest pain, coughing blood, confusion, or a high temperature during treatment. Profiling is a planning test and should not delay urgent assessment of a symptom. Follow the emergency instructions provided by your hospital if breathing suddenly becomes difficult or you feel severely unwell.

Which alterations does this test assess, and could the result change my treatment? How reliable is the sample for my cancer? What happens if the report is inconclusive or finds no actionable change?